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Background and Objective. We reviewed all unrelated
donor bone marrow transplants (UDBMT) performed in
Belgium up to December 1995 to identify prognostic
factors for relapse, transplant-related mortality and sur-
vival. 
Design and Methods. A total of 163 UDBMT were per-
formed in 92 males and 71 females aged 1-55 (medi-
an 26) years. Patients were transplanted for ALL
(n=35), AML (n=34), CML (n=51), other myeloid malig-
nancies (n=14), SAA (n=21) or miscellaneous other
diseases (n=8). Most patients had advanced disease;
a few patients were in CR1 (n=10) or early chronic
phase (CP) of CML (n=5). 
Results. Overall survival at 5 yrs was 17% (95% confi-
dence interval: 8-32%), but survival was significantly
better for patients with non-malignant disorders (55%
at 4 yrs). The relapse rate ±SE was projected to be 40
(28-54)% at 5 yrs, 36 (20-56)% for standard-risk and 68
(43-85)% for high-risk malignancies (p=0.0029). There
was no relapse in CML patients transplanted in 1st CP
compared to 68% at 4 yrs with more advanced CML
(p=0.0033). Grade II-IV acute graft-versus-host disease
(aGVHD) occurred in 55% by day 100 and was strong-
ly modulated by age, ranging from 41% in <20-yr-old to
80% in >40-yr-old patients (p=0.0021). Transplant-
related mortality (TRM) was projected to be 72 (52-
87)% at 5 yrs including 2 very late deaths from lung
fibrosis and secondary cancer. Main causes of death
were original disease in 27, secondary malignancy in
2, GVHD in 28, interstitial pneumonia in 21, other infec-
tions in 19, and miscellaneous toxic causes in 21
patients. In multivariate analysis, the relapse rate was
strongly dependent on the disease status (p=0.0029),
TRM being significantly worse with older age
(p=0.0049), and overall survival being significantly
worse in more advanced disease (p=0.0006), after a
second transplant (p=0.0166), in centers of smaller
size (p=0.0316) and in older patients (NS). 
Interpretation and Conclusions. Although results have
improved somewhat in recent years, UDBMT remains
a procedure with a high TRM. UDBMT should be per-
formed in patients with less advanced diseases and in
centers with more experience, particularly in the treat-
ment of adult patients.
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Allogeneic bone marrow transplantation (allo-BMT) has become the treatment of choice fora variety of hematologic malignancies, bone
marrow failures and congenital disorders of the lym-
phohematopoietic system. However, the majority of
patients who could benefit from an allo-BMT lack a
suitable family donor. Therefore, registries of unrelat-
ed volunteer marrow donors have been developed in
many countries, offering the possibility of unrelated
donor bone marrow transplantation (UDBMT).1-3
Compared to allo-BMT, UDBMT is usually associat-
ed with an increased risk of morbidity and transplant-
related mortality (TRM)4,5 and many physicians are
therefore reluctant to propose such a transplant as
early in the course of the disease as they would an
allo-BMT from an HLA-identical sibling. However,
similar to what has been observed for allo-BMT, out-
comes are significantly worse for patients in advanced
disease, both in terms of relapse and of TRM.5,6
Therefore, it may not be the most appropriate strat-
egy to reserve UDBMT primarily for these high-risk
patients. The Marrow Donor Program (MDP)-Bel-
gium was established to recruit volunteer donors and
facilitate marrow transplants from Belgian and for-
eign unrelated donors. The current retrospective
study was undertaken to evaluate the results of all
UDBMT performed in Belgium since the first one in
1983 till December 1995. The overall results were
poor and we tried to identify the reasons for this.
Design and Methods
We reviewed all unrelated donor bone marrow
transplants (UDBMT) performed in Belgium up to
December 31, 1995. A first questionnaire was sent to
all units involved in stem cell transplantation, asking
for a list of all transplants  performed in their center.
All centers responded and 163 UDBMT were identi-
fied. A second more detailed questionnaire was then
sent for each of these cases. Essential data were
obtained for all of them, although some details were
missing for 10 of them. These transplants were per-
formed by 10 teams, i.e. the Catholic University of
Leuven (n=36), the University of Liège (n=30), the
Catholic University of Louvain (Pediatrics) (n=22),
the University of Gent (n=20), the Catholic Universi-
ty of Louvain (Adults) (n=19), the Free University of
Brussels (n=11), University Clinics of Mont-Godinne
(n=10), the Bordet Institute (Free University of Brus-
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sels) (n=9), the University of Antwerp (n=3), and the
Reine Fabiola Hospital (Free University of Brussels)
(n=3).
There were 92 males and 71 females, aged 7
months to 55 (median 26) years. Patients were trans-
planted for ALL (n=35), AML (n=34), CML (n=51),
other myeloproliferative disorders (n=5), MDS (n=9),
NHL (n=2), multiple myeloma (n=1), SAA (n=21) or
genetic diseases (n=5). Among  the AML patients, 3
were in CR1, 10 in CR2 and 21 in more advanced dis-
ease. Among the ALL patients, 7 were in CR1, 17 in
CR2 and 11 in more advanced disease. Among the
CML patients, 27 were in chronic phase (very few
(n=5) within one year of diagnosis) and 24 in accel-
erated phase or blast crisis. Five patients were under-
going a second transplant, 4 for leukemic relapse and
1 for graft failure. 
The conditioning regimen included TBI in 125
patients, TLI in 4 and no irradiation in 27, whereas
details were not available for 7 cases. The condition-
ing regimen consisted of an association of cyclophos-
phamide, Ara-C and single-dose TBI in 66 cases,
cyclophosphamide and fractionated TBI in 21, TBI
with miscellaneous chemotherapeutic agents in 38 or
of busulfan-based regimens in 20 and other chemo-
therapeutic regimens in 11.
Donors were provided by the Marrow Donor Pro-
gram-Belgium in 30% of the cases and by foreign reg-
istries in 70% of the cases among which the Anthony
Nolan Research Center and France Transplant pro-
cured 50% of the donors. Donors and recipients were
HLA-matched by serology in all but 13 cases in the
direction of rejection and 9 cases in the direction of
graft-versus-host disease (GvHD) (major mismatch),
whereas complete data were not available for 12 cas-
es. The mixed lymphocyte reaction was compatible in
100, not compatible in 17, not performed in 20 and
non-contributive or unavailable for evaluation in 26
cases. Complete high-resolution DRB1 molecular
typing was available for only 59 patients and was
matched in 51 of them. 
All patients received bone marrow, which was T
cell depleted in 45 cases and unmanipulated in 111,
with no information available for 7 cases. GvHD pre-
vention was based on T-cell depletion in 45 patients,
cyclosporine alone in 7, cyclosporine + methotrexate
in 70, cyclosporine + ATG in 13, or a combination of
cyclosporine + methotrexate + ATG in 17. Other
agents were used in 2 patients and data were not
available for 9.
Univariate actuarial survival analyses were per-
formed using the Kaplan-Meier product-limit method
and presented as % survival (95% confidence inter-
vals). Comparisons between survival curves were made
using the log-rank test. Multivariate survival analyses
were carried out using the Cox proportional hazards
model, with year of transplant, center (pediatric, small
or large adult center), age, sex, BMT sequential num-
ber (1st or 2nd BMT), TBI (yes or no), serologic HLA
match (yes or no) and type of GvHD prevention (T
cell depletion, cyclosporine + methotrexate or other)
as covariates. Univariate analyses were carried out with
Graphpad Prism (Graphpad Software, San Diego, CA,
USA) and multivariate analyses with SAS (SAS Insti-
tute, Cary, NC, USA) software.
Results
Hematopoietic recovery and GvHD
Among day 30 survivors, WBC engraftment was
complete (1,000 PMN) in 94% of the cases, partial
(200 PMN) in 3% and absent in 3%, while platelet
engraftment was complete (100,000 Plts) in 45%,
partial (20,000 Plts without transfusion) in 31% and
absent in 24%. For patients surviving more than 100
days post-transplant, these figures of platelet engraft-
ment increased to 66%, 18% and 16%, respectively.
No acute GvHD (aGvHD) was noticed in 62
patients but this includes early deaths. The maximum
grade of aGvHD was grade I in 23, II in 28, III in 25
and IV in 14 patients. Data were not available in 8
patients and 3 additional patients had aGvHD that
was not clearly graded. The projected rate of grade II-
IV aGvHD was 55% at day 100, occurring before day
20 in half of the cases. This rate was strongly depen-
dent on age, ranging from 41% in patients <20 yrs, to
57% in patients 20-40 yrs, and to 80% in patients >40
yrs (p =0.0021). The use of ATG did not influence the
risk of aGvHD significantly. Chronic GvHD developed
in 25 of 92 patients surviving more than 100 days.
Relapses
Nine patients had persisting disease despite the
transplant procedure, 27 relapsed after documented
CR and 28 patients not in CR at the time of trans-
plant died too early to be evaluable for disease status.
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Figure 1. Kaplan-Meier estimates of the relapse rate in
patients with non-malignant disorders (n=26), standard-risk
malignancies (n=74) or advanced malignancies (n=63)
(p=0.0029). For non-malignant diseases, “relapse” was
defined as persistence or recurrence of original disease with
graft rejection.
Among patients with persisting or relapsed disease
after transplant, 27 died and 9 are still alive. The
relapse rate was projected to be 40 (28-54)% at 5 yrs
for all patients. Persistence or recurrence of original
disease occurred in 18 (6-41)% for non-malignant dis-
orders (SAA and genetic diseases), 36 (20-56)% for
standard-risk malignancies and 68 (43-85)% for high-
risk malignancies (p =0.0029). For AML patients, the
relapse rate was 40 (18-67)% for patients in CR1 or
CR2 and 63 (32-87)% for patients with more
advanced disease (NS). For ALL patients, these figures
were 52 (26-77)% for CR1-CR2 patients and 100% for
those with more advanced disease (p =0.0015). There
was no relapse in first chronic phase CML compared
to 68 (32-91)% in more advanced disease (p =0.033).
In the Cox analysis, only more advanced disease
(p =0.0004) and GvHD prevention with cyclosporine
and methotrexate (p=0.0036) were associated with a
high risk of relapse.
Causes of death
At the time of this analysis, 119 patients have died
and 44 are alive. The main causes of death as well as
any number of contributing causes of death are pre-
sented in Table 1. Twenty-seven patients died from
their original disease and 92 from transplant-related
causes, including 64 patients in documented CR and
28 patients who died too early to be evaluated for
disease status. Among 71 patients dying before day
100 post-transplant, aGvHD (n=18) was the leading
cause of death, followed by interstitial pneumonia
(n=12), other infections (n=10) and original disease
(n=7). Original disease (n=20) was the leading cause
of death after day 100, followed by chronic GvHD
(n=9) and miscellaneous infections (n=9). 
Transplant-related mortality
Age had a major impact on survival with projected
survival rates of 45%, 33% and 17% at 1 yr or 24%,
12% and 13% at 5 yrs, respectively for patients aged
<20, 20-40 and >40 years (p=0.0101). This was due
to a sharp increase in transplant-related mortality
(TRM) from 37% to 55% to 67% for the 3 age groups,
respectively (p=0.0049). Overall TRM was 50% (42-
58%) at 6 months and 72% (52-87%) at 5 yrs because
of 2 very late deaths due to idiopathic lung fibrosis
and a secondary malignancy. This was not different
among AML, ALL or CML patients, nor between stan-
dard-risk and high-risk malignancies. TRM tended to
be lower in patients with non-malignant diseases
(35% at 1 yr and 45% at 3 yrs) compared to patients
with malignant disorders (60% at 1 yr and 64% at 3
yrs) (p=0.0519). In the Cox analysis, only older age
was associated with a poor risk (p=0.0003).
Overall survival
Overall survival was projected to be 84% at 30 days,
56% at 100 days, 34% at one year and 17% (8-32%) at
5 through to 13 yrs (Figure 3). There was a trend for
improvement in survival in the 1992-1995 period com-
pared to earlier transplants (27% vs 14%, NS). Sur-
vival was 20% (9-39%) at 5 years in AML patients, with
no difference between CR and those transplanted in
more advanced disease. For ALL patients, the figure
was 15% (6-33%) at 3 years with a trend for better sur-
vival in patients transplanted in CR (21% at 3 yrs) than
those transplanted during more advanced disease (0%
at 2 yrs) although this did not reach statistical signif-
icance. Survival for CML patients was 18% (9-33%) at
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Figure 2. Kaplan-Meier estimates of transplant-related mor-
tality in patients 0-20 (N=64), 20-40 (N=64) or >40 yrs
(N=35) (p=0.0049).
Table 1. Primary and any number of contributing causes of
death in 119 patients.
Primary cause Contributing cause
Original disease 27 –
Secondary malignancy 2 0
Acute GvHD 19 14
Chronic GvHD 9 6
Interstitial pneumonia 16 15
Other pneumonia 3 5
Bacterial infection 4 11
Viral infection 2 3
Fungal infection 8 20
Parasitic infection 1 0
Unclassified infection 1 4
ARDS 5 20
Graft failure 4 5






5 yrs, with better survival for patients transplanted in
chronic phase than in accelerated or blast phase (32%
vs 5%, p<0.10). Patients with standard-risk malignan-
cies had a survival of 24% at 5 yrs, compared with 11%
at 4 yrs for advanced malignancies, while those with
non-malignant diseases had the best survival [55%
(32-75%) at 4 yrs, which dropped to 36% (17-62%)]
at 5 yrs because of the 2 very late deaths mentioned
above (p=0.0004). In the subgroup of SAA patients,
survival was 53% (30-75%) at 4 yrs and dropped to
32% (11-59%) at 5 yrs for the same reason. When
comparing 45 transplants performed in pediatric cen-
ters with 66 transplants performed in larger and 52 in
smaller adult centers, there was a significant differ-
ence, with 3-yr survival rates of 38%, 25% and 11%,
respectively (p=0.0054). In the Cox analysis, more
advanced disease (p=0.0006), second transplant
(p=0.0166) and smaller adult center size (p=0.0316)
were associated with poorer outcome.
Discussion
We reviewed the outcome of all 163 UDBMT car-
ried out in Belgium up to December 1995. Overall,
the results were poor, with only 17% of the patients
projected to remain alive in complete remission
beyond 5 years. This compares unfavorably with
results published by other registries.5-7 However, most
studies report survival at 2-3 years, a significantly
shorter follow-up than in our study. This is of impor-
tance, since lethal complications may occur late in
this setting as illustrated by our cases of secondary
cancer and idiopathic lung fibrosis. Additionally, our
study encompasses many years and results have
improved in the years since 1992, as observed by oth-
ers.8
Our disappointing findings may primarily stem
from the fact that most patients were in an advanced
phase of their disease. One exception was transplan-
tation for non-malignant disorders, for which we
obtained good results that compare favorably with
those reported in other studies,6,9,10 probably because
advanced stage is less of a problem in this setting. Of
all possible factors influencing the outcome of
UDBMT, disease status at transplant is of major
importance.3,5 The relationship between disease sta-
tus and outcome of UDBMT has been particularly
well established for CML, acute leukemias and
MDS.5,7,11-14 Patients with more advanced disease not
only relapse more frequently, but also have a higher
risk of TRM,5,12 probably because of extensive previ-
ous treatments. Even within the group of patients
with CML in first CP, survival is significantly worse
for patients transplanted beyond one year after diag-
nosis.12 In our series of patients, very few were trans-
planted within one year of diagnosis of CML, which
might explain why survival was only 32% in CML
patients transplanted in CP. Similarly, the relapse rate
in ALL CR2 was high even compared with those
reported for poor-risk patients,15 and this may reflect
the use of single dose instead of fractionated TBI in
some patients.
The reasons for transplanting patients late in the
course of their disease include the time necessary to
find a donor and the reluctance of physicians to pro-
pose a procedure perceived as highly risky until no
other option is available. The time from search initi-
ation to transplant has been reduced in recent years
by increasing the donor pool and emphasizing
prospective complete HLA-typing, including molecu-
lar typing, of donors newly recruited into registries.7,8
Recent studies have shown that in some instances
outcomes of UDBMT were comparable to those of
allo-BMT from a matched sibling16,17 or those of
autologous BMT.18 Results obtained by some indi-
vidual teams in CML patients transplanted in early
chronic phase are extremely encouraging,12,19 partic-
ularly when no interferon-a has been given.20 These
results should now convince physicians to consider
UDBMT as a valid first-line option for younger CML
patients or selected patients with poor-risk acute
leukemia. 
Among patient characteristics influencing survival
after UDBMT, age, consecutive number of transplant
and HLA-matching are usually considered as the most
meaningful. Marrow cell dose also is now recognized as
an important factor.14 Second transplants for relapse or
graft failure after autologous BMT or UDBMT are asso-
ciated with an increased risk of TRM as well as disease
resistance.6 Results in children are uniformly better than
in adults, partly due to an increased incidence of severe
acute GvHD and extensive chronic GvHD with older
recipient age.7,8,10,11,13,16,21-25 Although HLA matching did
not emerge as a significant prognostic factor in our
analysis, it is now considered of critical importance for
the outcome of UDBMT. This was evident for HLA
matching by serology in adults,5-8,26 possibly resulting in
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Figure 3. Kaplan-Meier estimates of overall survival in 163
UDBMT.
a low incidence of GvHD in some patient populations
closely matched to their donors.27,28 This was much
less evident in children in whom one minor (split anti-
gen or DRB1 molecular) mismatch or major (broad
antigen) mismatch was not associated with poorer out-
come.21-25 The recent availability of molecular typing
may improve the degree of matching, thus reducing the
risk of severe GvHD and improve outcome.29 The risk of
severe GvHD and TRM can be reduced by matching for
HLA-C,30,31 HLA-DRB1,32 HLA-DQB1,33 as well as HLA
class I alleles,34 but not for HLA-DPB1.35 High resolu-
tion HLA matching combining several techniques can
thus result in decreased mortality after UDBMT.3,36 This
may explain the better results obtained by us and oth-
er groups in more recent years.
Pediatric centers treated younger patients of whom
a higher proportion had non-malignant disorders;
their results were superior to those obtained in adult
transplant centers. Individual center’s experience of
UDBMT was also very important. Among adult trans-
plant centers, outcome was superior in centers with
greater experience compared with smaller centers.
This was true even if the only adult center trans-
planting younger patients with less advanced diseases
(and obtaining better results than the others) was
one of the small centers. This confirms the findings
of the IMUST study4 and emphasizes the need for a
considerable experience when carrying out these
high-risk procedures.
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